<DOC>
	<DOCNO>NCT01469507</DOCNO>
	<brief_summary>The primary objective study compare combination hyaluronic acid chondroitin sulfate ( V0220 ) HyalganÂ® pain relief patient symptomatic knee osteoarthritis ( OA ) 24 week administer three weekly injection . Chondroitin sulfate one component cartilage . Studies show chondroitin sulphate improve quality hyaluronic acid produce joint . The benefit V0220 combination base two main physicochemical property , line characteristic osteoarthritic disease : optimising rheological behaviour improve buffer effect synovial flow ( `` outflow buffer '' ) .</brief_summary>
	<brief_title>Efficacy Safety Study Patients Suffering From Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>present uni bilateral medial and/or lateral femorotibial osteoarthritis knee evolve 6 month patient take analgesic medication least 3 month prior randomisation dissatisfy current therapy isolate symptomatic femoropatellar osteoarthritis target knee prothesis undergone articular lavage , arthroscopy surgery target knee 6 month precede randomisation , target knee osteoarthritis clinical joint effusion selection randomization body mass index ( BMI ) great equal 30 , patient receive corticosteroid treatment administration route ( inhaler , ocular , auricular route ) month precede randomisation , patient receive intraarticular steroid injection target knee within month precede randomisation patient receive intraarticular hyaluronic acid target knee 6 month precede randomisation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>